Effect of viloxazine on serum carbamazepine levels in epileptic patients.
The present study describes the interaction between carbamazepine (CBZ) and viloxazine, a recently synthesized antidepressant agent. Seven epileptic patients on chronic anticonvulsant therapy showed a significant (p less than 0.005) increase in steady-state serum CBZ levels (from 8.1 +/- 2.5 SD to 12.1 +/- 2.5 SD micrograms/ml) when viloxazine (300 mg/day) was added to the therapy. The effect was associated with the appearance of mild CBZ intoxication. The symptoms of this intoxication (i.e., dizziness, ataxia, fatigue, drowsiness) disappeared rapidly, and serum CBZ levels decreased to the basal values, when viloxazine administration was stopped.
D000328:Adult; D002220:Carbamazepine / Q000097:blood* / Q000627:therapeutic use; D003863:Depression / Q000150:complications* / Q000188:drug therapy; D004347:Drug Interactions; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D014745:Viloxazine / Q000494:pharmacology* / Q000627:therapeutic use
D009025:Morpholines; D002220:Carbamazepine; D014745:Viloxazine